Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AYTU BIOPHARMA, INCAYTU · Entity 7560 | Director | June 08, 2020 | June 12, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AYTU BIOPHARMA, INC
Report date June 08, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2030-06-07 | Direct | 40,000 |
Reported balance
After 2020-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-08 · Grant · Acquired 40,000 · Balance 40,000 F2: 100% vest on June 7, 2021, subject to the Grantee's continued service as a director on such dates. |
| Common StockSEC Table I · non-derivative | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2020-06-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 75,000 F1: These are restricted shares which vest on January 8, 2030, subject to earlier vesting in certain situations. |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted shares which vest on January 8, 2030, subject to earlier vesting in certain situations.
F2: 100% vest on June 7, 2021, subject to the Grantee's continued service as a director on such dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2020 Filed Jun 12, 2020 21:37 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001654954-20-006576 · section16.xml · derivative · entry 2 Mehta Ketan Bhupatrai · CIK 0001758559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-06-07 F2 · derivative.exercise_date: 100% vest on June 7, 2021, subject to the Grantee's continued service as a director on such dates. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 13:30 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-20-000677 · section16.xml · nonDerivative · entry 1 Mehta Ketan Bhupatrai · CIK 0001758559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · price: These are restricted shares which vest on January 8, 2030, subject to earlier vesting in certain situations. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 21:00 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 65,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-19-001562 · section16.xml · nonDerivative · entry 1 Mehta Ketan Bhupatrai · CIK 0001758559 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 F1 · price: These are restricted shares which vest on February 13, 2029, subject to earlier vesting in certain situations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.